SR2211 is a synthetic RORγ-selective modulator that potently inhibits production of IL-17 in cells. In vitro, treatment of EL4 with SR2211 represses the IL-17 gene expression. Similarly, the expression of IL-23 receptor (Il23r) is significantly inhibited by SR2211. Treatment of EL-4 cells with SR2211 results in significant inhibition of IL-17 intracellular staining as compared to vehicle treated cells.
Molecular Weight | 527.48 |
Formula | C26H24F7N3O |
CAS Number | 1359164-11-6 |
Solubility (25°C) | DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related ROR Products |
---|
JTE-151
JTE-151 is a RORγ inhibitor that suppresses overactive immune responses by inhibiting RORγ associated with Th17 cell activation.JTE-151 can be used in studies related to autoimmune diseases. |
SAR-441169
SAR-441169 is a RORγt inverse agonist that can be used in studies related to psoriasis. |
GRC-39815
GRC-39815 is a RORγt inverse agonist that can be used in studies related to chronic obstructive pulmonary disease. |
RORγ antagonist 1
RORγ antagonist 1, a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). |
RORγt inverse agonist 31
RORγt inverse agonist 31 (14g) is a potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 0.428 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.